Oruka Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-25.1%projected annual EPS growth
Analyst Coverage
12analysts covering
FY EPS (est.)
-$2.28next fiscal year
Monitoring Framework
Key Performance Indicators
ORKA-001 EVERLAST-A PASI 100 Rate at Week 166,350.0%
ORKA-001 EVERLAST-A PASI 90 Rate at Week 168,300.0%
ORKA-001 EVERLAST-A IGA 0/1 Rate at Week 168,400.0%
Cash, Cash Equivalents, and Marketable Securities Quarterly496MTarget: Sufficient to fund operations through anticipated BLA filing for ORKA-001
Watch Items
- ORKA-001 EVERLAST-A 28-Week and 52-Week Follow-Up Data
- ORKA-002 Phase 2 Trial Initiation (ORCA-SURGE)Action: Monitor safety profile and prepare for initial data readouts expected in 2027
- Halozyme Hypercon Collaboration Milestones
Research as of 20 Jun 2026